Feasibility and impact of Lynch syndrome genetic testing in newly diagnosed colorectal cancer patients: a multicenter observational study in Greece
Background: Lynch syndrome (LS) is an autosomal dominant disorder associated with a heightened risk of specific cancers, caused by germline mutations in the mismatch repair (MMR) system, which leads to microsatellite instability (MSI). MSI-positive colorectal cancer (CRC) patients have an increased...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | ESMO Gastrointestinal Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2949819825000226 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850103546221953024 |
|---|---|
| author | S. Manolakou N. Tsoukalas E. Saloustros T. Makatsoris I. Boukovinas A. Christopoulou A. Karampeazis I. Bompolaki I.-I. Varthalitis E. Voulgaris K. Ballasis A. Boutis E. Galani C. Kalofonos A. Koumarianou C. Kourousis P. Papakotoulas C. Papandreou E.-I. Perdikouri A. Andreadou I. Athanasiadis F.-I. Dimitrakopoulos C. Emmanouilidis E. Kampletsas O. Katopodi P. Kosmidis K. Koutsoukos E. Lianos P. Makrantonakis E. Ntouvelis C. Panopoulos V. Papadopoulos G. Pentheroudakis E. Samantas I. Stoupis G. Tsironis N. Chatzifoti I. Souglakos Z. Saridaki |
| author_facet | S. Manolakou N. Tsoukalas E. Saloustros T. Makatsoris I. Boukovinas A. Christopoulou A. Karampeazis I. Bompolaki I.-I. Varthalitis E. Voulgaris K. Ballasis A. Boutis E. Galani C. Kalofonos A. Koumarianou C. Kourousis P. Papakotoulas C. Papandreou E.-I. Perdikouri A. Andreadou I. Athanasiadis F.-I. Dimitrakopoulos C. Emmanouilidis E. Kampletsas O. Katopodi P. Kosmidis K. Koutsoukos E. Lianos P. Makrantonakis E. Ntouvelis C. Panopoulos V. Papadopoulos G. Pentheroudakis E. Samantas I. Stoupis G. Tsironis N. Chatzifoti I. Souglakos Z. Saridaki |
| author_sort | S. Manolakou |
| collection | DOAJ |
| description | Background: Lynch syndrome (LS) is an autosomal dominant disorder associated with a heightened risk of specific cancers, caused by germline mutations in the mismatch repair (MMR) system, which leads to microsatellite instability (MSI). MSI-positive colorectal cancer (CRC) patients have an increased likelihood of LS. Despite this, LS germline genetic testing is not reimbursed by the National Health Authorities in Greece. To address this gap, the Hellenic Society of Medical Oncology (HeSMO) initiated a national program to screen and diagnose CRC patients with LS. Materials and methods: From 2017 to 2019, 151 newly diagnosed CRC patients in Greece were enrolled. MSI molecular analysis was carried out, followed by next-generation sequencing (NGS) germline testing in MSI patients without sporadic alterations to identify LS. Results: Of the patients, 76 (51.7%) exhibited MMR deficiency, with their tumors more likely to have mucinous histology (P < 0.001) and stage II disease (P = 0.015). Fourteen patients with MSH2, MSH6, or PMS2 deficiency directly underwent germline analysis, and all were positive for LS. Sixteen MSI patients (20.5%) had sporadic BRAFV600E mutations, and another 16 had MLH1 promoter hypermethylation. Of the remaining 32 patients tested for germline mutations, 8 were positive for LS, accounting for 15% of CRC patients—a 2.9-fold greater proportion than expected, according to historic records. Testing asymptomatic relatives identified two first-degree relatives with MSH2 mutations. Conclusions: These findings underscore the critical need for CRC-adapted preventive oncology and support the implementation of a national LS screening program in Greece, aligned with international guidelines. |
| format | Article |
| id | doaj-art-b089f8fdb6924b7cb5e16ff5b0e55c08 |
| institution | DOAJ |
| issn | 2949-8198 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | ESMO Gastrointestinal Oncology |
| spelling | doaj-art-b089f8fdb6924b7cb5e16ff5b0e55c082025-08-20T02:39:31ZengElsevierESMO Gastrointestinal Oncology2949-81982025-06-01810015310.1016/j.esmogo.2025.100153Feasibility and impact of Lynch syndrome genetic testing in newly diagnosed colorectal cancer patients: a multicenter observational study in GreeceS. Manolakou0N. Tsoukalas1E. Saloustros2T. Makatsoris3I. Boukovinas4A. Christopoulou5A. Karampeazis6I. Bompolaki7I.-I. Varthalitis8E. Voulgaris9K. Ballasis10A. Boutis11E. Galani12C. Kalofonos13A. Koumarianou14C. Kourousis15P. Papakotoulas16C. Papandreou17E.-I. Perdikouri18A. Andreadou19I. Athanasiadis20F.-I. Dimitrakopoulos21C. Emmanouilidis22E. Kampletsas23O. Katopodi24P. Kosmidis25K. Koutsoukos26E. Lianos27P. Makrantonakis28E. Ntouvelis29C. Panopoulos30V. Papadopoulos31G. Pentheroudakis32E. Samantas33I. Stoupis34G. Tsironis35N. Chatzifoti36I. Souglakos37Z. Saridaki38Hellenic Society of Medical Oncology (HeSMO), Athens, GreeceHellenic Society of Medical Oncology (HeSMO), Athens, GreeceHellenic Society of Medical Oncology (HeSMO), Athens, GreeceHellenic Society of Medical Oncology (HeSMO), Athens, GreeceHellenic Society of Medical Oncology (HeSMO), Athens, GreeceHellenic Society of Medical Oncology (HeSMO), Athens, GreeceHellenic Society of Medical Oncology (HeSMO), Athens, GreeceHellenic Society of Medical Oncology (HeSMO), Athens, GreeceHellenic Society of Medical Oncology (HeSMO), Athens, GreeceHellenic Society of Medical Oncology (HeSMO), Athens, GreeceHellenic Society of Medical Oncology (HeSMO), Athens, GreeceHellenic Society of Medical Oncology (HeSMO), Athens, GreeceHellenic Society of Medical Oncology (HeSMO), Athens, GreeceHellenic Society of Medical Oncology (HeSMO), Athens, GreeceHellenic Society of Medical Oncology (HeSMO), Athens, GreeceHellenic Society of Medical Oncology (HeSMO), Athens, GreeceHellenic Society of Medical Oncology (HeSMO), Athens, GreeceHellenic Society of Medical Oncology (HeSMO), Athens, GreeceHellenic Society of Medical Oncology (HeSMO), Athens, GreeceHellenic Society of Medical Oncology (HeSMO), Athens, GreeceHellenic Society of Medical Oncology (HeSMO), Athens, GreeceHellenic Society of Medical Oncology (HeSMO), Athens, GreeceHellenic Society of Medical Oncology (HeSMO), Athens, GreeceHellenic Society of Medical Oncology (HeSMO), Athens, GreeceHellenic Society of Medical Oncology (HeSMO), Athens, GreeceHellenic Society of Medical Oncology (HeSMO), Athens, GreeceHellenic Society of Medical Oncology (HeSMO), Athens, GreeceHellenic Society of Medical Oncology (HeSMO), Athens, GreeceHellenic Society of Medical Oncology (HeSMO), Athens, GreeceHellenic Society of Medical Oncology (HeSMO), Athens, GreeceHellenic Society of Medical Oncology (HeSMO), Athens, GreeceHellenic Society of Medical Oncology (HeSMO), Athens, GreeceHellenic Society of Medical Oncology (HeSMO), Athens, GreeceHellenic Society of Medical Oncology (HeSMO), Athens, GreeceHellenic Society of Medical Oncology (HeSMO), Athens, GreeceHellenic Society of Medical Oncology (HeSMO), Athens, GreeceHellenic Society of Medical Oncology (HeSMO), Athens, GreeceHellenic Society of Medical Oncology (HeSMO), Athens, GreeceHellenic Society of Medical Oncology (HeSMO), Athens, Greece; Correspondence to: Dr Zenia Saridaki, Hellenic Society of Medical Oncology (HeSMO), 105, Alexandras Avenue, 11475, Athens, Greece. Tel: +302106457971Background: Lynch syndrome (LS) is an autosomal dominant disorder associated with a heightened risk of specific cancers, caused by germline mutations in the mismatch repair (MMR) system, which leads to microsatellite instability (MSI). MSI-positive colorectal cancer (CRC) patients have an increased likelihood of LS. Despite this, LS germline genetic testing is not reimbursed by the National Health Authorities in Greece. To address this gap, the Hellenic Society of Medical Oncology (HeSMO) initiated a national program to screen and diagnose CRC patients with LS. Materials and methods: From 2017 to 2019, 151 newly diagnosed CRC patients in Greece were enrolled. MSI molecular analysis was carried out, followed by next-generation sequencing (NGS) germline testing in MSI patients without sporadic alterations to identify LS. Results: Of the patients, 76 (51.7%) exhibited MMR deficiency, with their tumors more likely to have mucinous histology (P < 0.001) and stage II disease (P = 0.015). Fourteen patients with MSH2, MSH6, or PMS2 deficiency directly underwent germline analysis, and all were positive for LS. Sixteen MSI patients (20.5%) had sporadic BRAFV600E mutations, and another 16 had MLH1 promoter hypermethylation. Of the remaining 32 patients tested for germline mutations, 8 were positive for LS, accounting for 15% of CRC patients—a 2.9-fold greater proportion than expected, according to historic records. Testing asymptomatic relatives identified two first-degree relatives with MSH2 mutations. Conclusions: These findings underscore the critical need for CRC-adapted preventive oncology and support the implementation of a national LS screening program in Greece, aligned with international guidelines.http://www.sciencedirect.com/science/article/pii/S2949819825000226Lynch syndromecolorectal cancermicrosatellite instabilitypreventionscreening programpreventive oncology |
| spellingShingle | S. Manolakou N. Tsoukalas E. Saloustros T. Makatsoris I. Boukovinas A. Christopoulou A. Karampeazis I. Bompolaki I.-I. Varthalitis E. Voulgaris K. Ballasis A. Boutis E. Galani C. Kalofonos A. Koumarianou C. Kourousis P. Papakotoulas C. Papandreou E.-I. Perdikouri A. Andreadou I. Athanasiadis F.-I. Dimitrakopoulos C. Emmanouilidis E. Kampletsas O. Katopodi P. Kosmidis K. Koutsoukos E. Lianos P. Makrantonakis E. Ntouvelis C. Panopoulos V. Papadopoulos G. Pentheroudakis E. Samantas I. Stoupis G. Tsironis N. Chatzifoti I. Souglakos Z. Saridaki Feasibility and impact of Lynch syndrome genetic testing in newly diagnosed colorectal cancer patients: a multicenter observational study in Greece ESMO Gastrointestinal Oncology Lynch syndrome colorectal cancer microsatellite instability prevention screening program preventive oncology |
| title | Feasibility and impact of Lynch syndrome genetic testing in newly diagnosed colorectal cancer patients: a multicenter observational study in Greece |
| title_full | Feasibility and impact of Lynch syndrome genetic testing in newly diagnosed colorectal cancer patients: a multicenter observational study in Greece |
| title_fullStr | Feasibility and impact of Lynch syndrome genetic testing in newly diagnosed colorectal cancer patients: a multicenter observational study in Greece |
| title_full_unstemmed | Feasibility and impact of Lynch syndrome genetic testing in newly diagnosed colorectal cancer patients: a multicenter observational study in Greece |
| title_short | Feasibility and impact of Lynch syndrome genetic testing in newly diagnosed colorectal cancer patients: a multicenter observational study in Greece |
| title_sort | feasibility and impact of lynch syndrome genetic testing in newly diagnosed colorectal cancer patients a multicenter observational study in greece |
| topic | Lynch syndrome colorectal cancer microsatellite instability prevention screening program preventive oncology |
| url | http://www.sciencedirect.com/science/article/pii/S2949819825000226 |
| work_keys_str_mv | AT smanolakou feasibilityandimpactoflynchsyndromegenetictestinginnewlydiagnosedcolorectalcancerpatientsamulticenterobservationalstudyingreece AT ntsoukalas feasibilityandimpactoflynchsyndromegenetictestinginnewlydiagnosedcolorectalcancerpatientsamulticenterobservationalstudyingreece AT esaloustros feasibilityandimpactoflynchsyndromegenetictestinginnewlydiagnosedcolorectalcancerpatientsamulticenterobservationalstudyingreece AT tmakatsoris feasibilityandimpactoflynchsyndromegenetictestinginnewlydiagnosedcolorectalcancerpatientsamulticenterobservationalstudyingreece AT iboukovinas feasibilityandimpactoflynchsyndromegenetictestinginnewlydiagnosedcolorectalcancerpatientsamulticenterobservationalstudyingreece AT achristopoulou feasibilityandimpactoflynchsyndromegenetictestinginnewlydiagnosedcolorectalcancerpatientsamulticenterobservationalstudyingreece AT akarampeazis feasibilityandimpactoflynchsyndromegenetictestinginnewlydiagnosedcolorectalcancerpatientsamulticenterobservationalstudyingreece AT ibompolaki feasibilityandimpactoflynchsyndromegenetictestinginnewlydiagnosedcolorectalcancerpatientsamulticenterobservationalstudyingreece AT iivarthalitis feasibilityandimpactoflynchsyndromegenetictestinginnewlydiagnosedcolorectalcancerpatientsamulticenterobservationalstudyingreece AT evoulgaris feasibilityandimpactoflynchsyndromegenetictestinginnewlydiagnosedcolorectalcancerpatientsamulticenterobservationalstudyingreece AT kballasis feasibilityandimpactoflynchsyndromegenetictestinginnewlydiagnosedcolorectalcancerpatientsamulticenterobservationalstudyingreece AT aboutis feasibilityandimpactoflynchsyndromegenetictestinginnewlydiagnosedcolorectalcancerpatientsamulticenterobservationalstudyingreece AT egalani feasibilityandimpactoflynchsyndromegenetictestinginnewlydiagnosedcolorectalcancerpatientsamulticenterobservationalstudyingreece AT ckalofonos feasibilityandimpactoflynchsyndromegenetictestinginnewlydiagnosedcolorectalcancerpatientsamulticenterobservationalstudyingreece AT akoumarianou feasibilityandimpactoflynchsyndromegenetictestinginnewlydiagnosedcolorectalcancerpatientsamulticenterobservationalstudyingreece AT ckourousis feasibilityandimpactoflynchsyndromegenetictestinginnewlydiagnosedcolorectalcancerpatientsamulticenterobservationalstudyingreece AT ppapakotoulas feasibilityandimpactoflynchsyndromegenetictestinginnewlydiagnosedcolorectalcancerpatientsamulticenterobservationalstudyingreece AT cpapandreou feasibilityandimpactoflynchsyndromegenetictestinginnewlydiagnosedcolorectalcancerpatientsamulticenterobservationalstudyingreece AT eiperdikouri feasibilityandimpactoflynchsyndromegenetictestinginnewlydiagnosedcolorectalcancerpatientsamulticenterobservationalstudyingreece AT aandreadou feasibilityandimpactoflynchsyndromegenetictestinginnewlydiagnosedcolorectalcancerpatientsamulticenterobservationalstudyingreece AT iathanasiadis feasibilityandimpactoflynchsyndromegenetictestinginnewlydiagnosedcolorectalcancerpatientsamulticenterobservationalstudyingreece AT fidimitrakopoulos feasibilityandimpactoflynchsyndromegenetictestinginnewlydiagnosedcolorectalcancerpatientsamulticenterobservationalstudyingreece AT cemmanouilidis feasibilityandimpactoflynchsyndromegenetictestinginnewlydiagnosedcolorectalcancerpatientsamulticenterobservationalstudyingreece AT ekampletsas feasibilityandimpactoflynchsyndromegenetictestinginnewlydiagnosedcolorectalcancerpatientsamulticenterobservationalstudyingreece AT okatopodi feasibilityandimpactoflynchsyndromegenetictestinginnewlydiagnosedcolorectalcancerpatientsamulticenterobservationalstudyingreece AT pkosmidis feasibilityandimpactoflynchsyndromegenetictestinginnewlydiagnosedcolorectalcancerpatientsamulticenterobservationalstudyingreece AT kkoutsoukos feasibilityandimpactoflynchsyndromegenetictestinginnewlydiagnosedcolorectalcancerpatientsamulticenterobservationalstudyingreece AT elianos feasibilityandimpactoflynchsyndromegenetictestinginnewlydiagnosedcolorectalcancerpatientsamulticenterobservationalstudyingreece AT pmakrantonakis feasibilityandimpactoflynchsyndromegenetictestinginnewlydiagnosedcolorectalcancerpatientsamulticenterobservationalstudyingreece AT entouvelis feasibilityandimpactoflynchsyndromegenetictestinginnewlydiagnosedcolorectalcancerpatientsamulticenterobservationalstudyingreece AT cpanopoulos feasibilityandimpactoflynchsyndromegenetictestinginnewlydiagnosedcolorectalcancerpatientsamulticenterobservationalstudyingreece AT vpapadopoulos feasibilityandimpactoflynchsyndromegenetictestinginnewlydiagnosedcolorectalcancerpatientsamulticenterobservationalstudyingreece AT gpentheroudakis feasibilityandimpactoflynchsyndromegenetictestinginnewlydiagnosedcolorectalcancerpatientsamulticenterobservationalstudyingreece AT esamantas feasibilityandimpactoflynchsyndromegenetictestinginnewlydiagnosedcolorectalcancerpatientsamulticenterobservationalstudyingreece AT istoupis feasibilityandimpactoflynchsyndromegenetictestinginnewlydiagnosedcolorectalcancerpatientsamulticenterobservationalstudyingreece AT gtsironis feasibilityandimpactoflynchsyndromegenetictestinginnewlydiagnosedcolorectalcancerpatientsamulticenterobservationalstudyingreece AT nchatzifoti feasibilityandimpactoflynchsyndromegenetictestinginnewlydiagnosedcolorectalcancerpatientsamulticenterobservationalstudyingreece AT isouglakos feasibilityandimpactoflynchsyndromegenetictestinginnewlydiagnosedcolorectalcancerpatientsamulticenterobservationalstudyingreece AT zsaridaki feasibilityandimpactoflynchsyndromegenetictestinginnewlydiagnosedcolorectalcancerpatientsamulticenterobservationalstudyingreece |